About: Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $7.36 (+0.96%)
OCUL NASDAQ Ocular Therapeutix Inc
Ocular Therapeutix Inc share price
Atividade de preço de OCUL
Último preço
$ 7,360
Variação (24h)
0,07 USD (0,96%)
Volume
1.46M
Volume (média 4 sem.)
-
Abertura
$ 7,36
Variação do dia
$ 7,31 - $ 7,54
Fechamento anterior
$ 7,29
Último negócio
29 Oct, 7:36 pm GMT+0
Atrasado
29 Oct, 7:36 pm GMT+0
OCUL price performance
Atrasado
29 Oct, 7:36 pm GMT+0
quote.marketSignals